Long Term Use of Megestrol Acetate by Cancer Survivors for the Treatment of Hot Flashes

Quella, Susan K.; Loprinzi, Charles L.; Sloan, Jeff A.; Vaught, Nancy L.; DeKrey, Wanda L.; Fischer, Tammy; Finck, Gwen; Pierson, Namali; Pisansky, Thomas M.

doi:10.1016/s0022-5347(01)62161-x

Cited by 11 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reasons for interruption of treatment were skin rashes, dyspnea, gastric pain, and increased arterial blood pressure. More clinical studies showed that depomedroxyprogesterone acetate and medroxyprogesterone acetate are effective in the treatment of hot flashes [71][72][73][74].…”

Section: Progestagensmentioning

confidence: 99%

Symptoms and Treatment in Cancer Therapy-Induced Early Menopause

2006

View full text Add to dashboard Cite

Young women with breast cancer often experience early menopause as a result of the therapy for their malignant disease. The sudden occurrence of menopause resulting from chemotherapy, oophorectomy, radiation, or gonadal dysgenesis frequently results in hot flashes that begin at a younger age and may occur at a greater frequency and intensity than hot flashes associated with natural menopause.Hormone therapy relieves symptoms effectively in 80%-90% of women who initiate treatment. This therapy, however, is generally contraindicated in estrogendependent cancers, such as breast cancer, because of the potentially increased risk for recurrence. Many agents have been investigated as potential means for alleviating hot flashes in survivors of breast cancer, such as progestagens, clonidine, gabapentin, and antidepressants. Several complementary and alternative medicines frequently used by patients have also been studied. These include black cohosh, phytoestrogens, homeopathy, vitamin E, acupuncture, and behavior strategies.To support the use of one of more of these nonpharmacological or pharmacological options in the treatment of hot flashes in breast cancer patients, more evidence from well-controlled clinical trials is needed. In particular, soundly based scientific research with complementary and alternative medicine therapies is lacking. Pharmacological treatments appear to be more beneficial than nonpharmacological treatments.This article reviews the current literature to assess the epidemiology and diagnosis of hot flashes and the nonpharmacological and pharmacological options for the treatment of hot flashes, in breast cancer patients in particular. When specific treatment options have not been evaluated in breast cancer patients specifically, published data on the management of hot flashes with this modality in healthy postmenopausal women are described. The Oncologist 2006;11:641-654 Learning ObjectivesAfter completing this course, the reader will be able to:1. Describe the therapeutic options when hot flashes disrupt the quality of life or quality of sleep in breast cancer patients.2. Select appropriate nonpharmacological or pharmacological options in the management of hot flashes in breast cancer patients.3. Discuss the relative efficacy and safety of interventions in the treatment of hot flashes in breast cancer patients.Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

Section: Progestagensmentioning

confidence: 99%

Symptoms and Treatment in Cancer Therapy-Induced Early Menopause

2006

View full text Add to dashboard Cite

show abstract

“…This concern has broader implications because of the common use of MA to block hot flashes in men on androgen-deprivation therapy. 46 Observation of these patients for an apparent flare in disease after the initiation of MA for these indications seems prudent.…”

Section: Discussionmentioning

confidence: 99%

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

Dawson

Conaway

Halabi³

et al. 2000

Cancer

View full text Add to dashboard Cite

show abstract

“…Studies on lipid profiles in women using a LNG-IUS in conjunction with systemic oestrogen are reassuring and overall show a neutral profile. 3 Insertion of a LNG-IUS in a menopausal woman can be technically difficult, and smaller devices are in development. Wollter-Svenson et al studied over 100 women who were randomised to receive a smaller LNG-IUS releasing either 5 or 10 m g levonorgestrel per 24 hours in conjunction with systemic oestrogen.…”

Section: Martin K Oehler Nuffield Dept Of Obstetrics and Gynaecologymentioning

confidence: 99%

“…2 Low-dose progestogens and tibolone appear to confer significant symptom control but long-term controlled data on their efficacy and safety in breast cancer survivors are lacking. 3,4 The most recent and comprehensive re-analysis of observational HRT studies reported an increase in breast cancer risk with long-term exposure (calculated relative risk for a median duration of use of 11 years 1.35, 95% confidence interval 1.21-1.49). In absolute terms, this probably accounts for only two extra cancers per 1,000 women who use HRT for five years.…”

Section: Martin K Oehler Nuffield Dept Of Obstetrics and Gynaecologymentioning

confidence: 99%

Endometrial angiogenic growth factors in the abnormal bleeding induced by hormone replacement therapy

Oehler

2000

British Menopause Society Journal

View full text Add to dashboard Cite

Long Term Use of Megestrol Acetate by Cancer Survivors for the Treatment of Hot Flashes

Cited by 11 publications

References 0 publications

Symptoms and Treatment in Cancer Therapy-Induced Early Menopause

Symptoms and Treatment in Cancer Therapy-Induced Early Menopause

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

Endometrial angiogenic growth factors in the abnormal bleeding induced by hormone replacement therapy

Contact Info

Product

Resources

About